Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024 report and make more profitable business decisions.
Primary progressive multiple sclerosis (PPMS) is a rare and disabling form of MS that affects the brain, spinal cord, and optic nerves. Unlike other types of MS, PPMS does not have relapses or remissions, but causes steady worsening of neurological functions from the onset. PPMS affects about 10% of people with MS, and it occurs equally in men and women. The average age of diagnosis is around 40 years. The symptoms of PPMS vary from person to person, but they often include problems with walking, balance, vision, muscle weakness, pain, fatigue, cognitive impairment, and bladder and bowel dysfunction. There is no cure for PPMS, but treatments can help manage symptoms and improve quality of life. PPMS is diagnosed based on clinical history, physical examination, MRI scans, spinal fluid analysis, and other tests.
The Primary Progressive Multiple Sclerosis (PPMS) drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Primary Progressive Multiple Sclerosis (PPMS) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 31 molecules, with 29 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Primary Progressive Multiple Sclerosis (PPMS) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Primary Progressive Multiple Sclerosis (PPMS) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Primary Progressive Multiple Sclerosis (PPMS) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AB Science SAAbata Therapeutics
AbbVie Inc
Alexion Pharmaceuticals Inc
Apimeds Inc
Asdera LLC
Biogen Inc
BrainStorm Cell Therapeutics Inc
Clene Inc
Denali Therapeutics Inc
Duke University
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Glialogix Inc
GlobeStar Therapeutics Corp
Guangzhou Lupeng Pharmaceutical Co Ltd
Immunic Inc
Imstem Biotechnology Inc
InnoBioscience LLC
JURA Bio Inc
Mapi Pharma Ltd
MedDay SA
MediciNova Inc
Millennium Pharmaceuticals Inc
Mitochon Pharmaceuticals Inc
Neuvivo Inc
PolTREG SA
Sanofi
Statera Biopharma Inc
Sungkyunkwan University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Primary Progressive Multiple Sclerosis (PPMS) reports